DAY 1

January 12th, 2024

DAY 2

January 13th, 2024

DAY 3

January 14th, 2024

Individual sessions

Summary of the ACR guidelines on the CTD ILD

Elana J. Bernstein, (USA)

Genetic predisposition and ILD?

Bruno Crestani (Paris)

Lecture: Immunosuppressors and anti-fibrotic for CTD-ILDs (SSc and RA), to combine or not to combine?

Vincent Cottin (Lyon)

Lecture: Immunosuppressors and anti-fibrotic for CTD-ILDs (SSc and RA), to combine or not to combine?

Philippe Dieude (Paris)

Role of AI tools/ quantification to imaging and reports

Jonathan Goldin (USA)

Drug toxicity in ILD

Nik Hirani (United Kingdom)

Diagnosis vs Screening vs Monitoring

Ann Hoffman Vold (Norway)

Treatment of PH in ILD, what to do and what to be avoided

Gabor Kovacs

Should we rely on imaging pattern for treatment decisions

Fernando Martinez (USA)

Summary of the ATS Guidelines on the CTD.ILD

Ganesh Raghu, (USA)

IPAF, is it time to move on?

Elisabetta Renzoni (United Kingdom)

PAH and PH-ILD how to differentiate

Olivier Sitbon (Paris)

IF, WHEN and HOW screening of ILD in RA and inflammatory arthritis

Jeffrey Sparks, (USA)

Should we rely on imaging pattern for treatment decisions

Nicola Sverzellati (Parma)

ILA and CTDs: a new kid on the block?

Sara Tomassetti (Florence)

WHEN to screen and DETECTION, what is POSITIVE, what is NEGATIVE, when to RE-SCREEN (ILA vs. ILD)

Ella Kazerooni (USA)